Spero Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Spero Therapeutics

14/11/2022 22:02

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of 33 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 30 cents per share.
    * Revenue fell 34.5% to $2.01 million from a year ago;
analysts
expected $5.42 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 33 cents​.
    * The mean earnings estimate of analysts had fallen by
about 21.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Spero Therapeutics Inc shares had held steady so far this
quarter and lost 87.5% so far this year.
    * The company reported a quarterly loss of $11.68 million.
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 10:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.30          -0.33          Missed
 Jun. 30 2022      -0.93          -0.87          Beat
 Mar. 31 2022      -0.87          -1.01          Missed
 Dec. 31 2021      -0.75          -0.90          Missed